Regeneron Has Research On The BrainFleur Templeton
Even by the standards of the biotech industry, Regeneron Pharmaceuticals Inc. is on a particularly daunting quest. It is one of a handful of companies focusing on the body's most complex mechanism, the brain. And it is pursuing treatments for deadly diseases without assurance that ways will be found to escort these drugs through the blood-brain barrier that protects the organ. It might hardly seem worth the effort but for the chance to find miracle cures and someday capture markets worth billions. And except for this: Dr. Leonard S. Schleifer, a neurologist and Regeneron's 40-year-old founder, has a plan to last the long haul.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Bitcoin Plunge Extends to 25% as Fear of Crypto Crackdown Linger
- America’s Fastest Spy Plane May Be Back—and Hypersonic
- GE CEO Renews Pledge to Study Breakup After $6.2 Billion Stumble
- The World's Top-Selling Video Game Has a Cheating Problem
- One of the Biggest Diamonds in History Has Just Been Dug Up